Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Implementing biomarker-driven strategies in RCC

Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, talks on the implementation of biomarker-driven strategies in renal cell carcinoma (RCC). Prof. Grünwald feels that personalized patient management approaches are the way forward in RCC, but a lack of reliable, high-resolution biomarkers is holding back progress. Lots of research is underway in this field and it is hoped that in the near future, there will be an improved understanding of how to select patients for treatment based on biomarkers. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Viktor Grünwald, MD has received advisory roles for BMS, MSD, EISAI, EUSAPharm, Merck-Serono, Nanobiotix, Pfizer and Roche; speaker’s honoraria for AstraZeneca, BMS, MSD, EISAI, Ipsen, Janssen-Cilag, Merck-Serono, Pfizer and Roche; stocks in AstraZeneca, BMS, MSD and SeattleGenetics; research grants from AstraZeneca, BMS, MSD, Ipsen and Pfizer; is a steering committee member for BMS, EISAI, Ipsen, Novartis and PharmaMar.